IP Library Patent Application 14296832
Patent Application
App. No. 14/296,832

PANCREATIC ENZYME COMPOSITIONS AND METHODS FOR TREATING PANCREATITIS AND PANCREATIC INSUFFICIENCY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/296,832
Abstract

Compositions of the present invention, comprising the combination of enterically coated and uncoated pancreatic enzyme-containing beads are useful for treating or preventing pancreatitis pain, and optionally disorders associated with digestive enzyme deficiencies.

Claims (27)

1 . A multi-particulate digestive enzyme composition comprising enterically coated digestive enzyme-containing beads, and uncoated digestive enzyme-containing beads, wherein:

the enterically coated digestive enzyme-containing beads comprise a core and an enteric coating disposed over the core, wherein the core comprises a therapeutically effective amount of digestive enzymes, and the enteric coating comprises an enteric polymer; and

the uncoated digestive enzyme-containing beads comprise a therapeutically effective amount of digestive enzymes, and is substantially free of an enteric polymer coating.

2 . The multi-particulate digestive enzyme composition of claim 1 , wherein the digestive enzymes comprise lipase and protease, and the ratio of lipase and protease activities in the enterically coated digestive enzyme-containing beads to the lipase and protease activities in the uncoated digestive enzyme-containing beads ranges from about 5:95 to about 50:50.

3 . The multi-particulate digestive enzyme composition of claim 1 , wherein the digestive enzymes comprise lipase and protease, and the ratio of lipase and protease activities in the enterically coated digestive enzyme-containing beads to the lipase and protease activities in the uncoated digestive enzyme-containing beads ranges from about 5:95 to about 25:75.

4 . The multi-particulate digestive enzyme composition of claim 1 , wherein the digestive enzymes comprise lipase and protease, and each of the enterically coated and uncoated digestive enzyme-containing beads have substantially the same protease and lipase activity.

5 . A dosage form comprising the multi-particulate digestive enzyme composition of claim 1 .

6 . The dosage form of claim 5 , wherein the enterically coated digestive enzyme-containing beads have a total lipase activity ranging from about 2000 USP lipase units to about 10,000 USP lipase units.

7 . The dosage form of claim 5 , wherein the enterically coated digestive enzyme-containing beads have a total protease activity ranging from about 6800 USP protease units to about 34,000 USP protease units.

8 . The dosage form of claim 6 , wherein the enterically coated digestive enzyme-containing beads have a total protease activity ranging from about 6800 USP protease units to about 34,000 USP protease units.

9 . The dosage form of claim 5 , wherein the uncoated digestive enzyme-containing beads have a total lipase activity ranging from about 10,000 USP lipase units to about 18,000 USP lipase units.

10 . The dosage form of claim 5 , wherein the uncoated digestive enzyme-containing beads have a total protease activity ranging from about 34,000 USP protease units to about 62,000 USP protease units.

11 . The dosage form of claim 9 , wherein the uncoated digestive enzyme-containing beads have a total protease activity ranging from about 34,000 USP protease units to about 62,000 USP protease units.

12 . The dosage form of claim 5 , wherein the enterically coated digestive enzyme-containing beads have a total lipase activity ranging from about 2000 USP lipase units to about 4,000 USP lipase units

13 . The dosage form of claim 5 , wherein the enterically coated digestive enzyme-containing beads have a total protease activity ranging from about 6800 USP protease units to about 13,600 USP protease units.

14 . The dosage form of claim 12 , wherein the enterically coated digestive enzyme-containing beads have a total protease activity ranging from about 6800 USP protease units to about 13,600 USP protease units.

15 . The dosage form of claim 5 , wherein the uncoated digestive enzyme-containing beads have a total lipase activity ranging from about 14,000 USP lipase units to about 18,000 USP lipase units.

16 . The dosage form of claim 5 , wherein the uncoated digestive enzyme-containing beads have a total protease activity ranging from about 47,000 USP protease units to about 62,000 USP protease units.

17 . The dosage form of claim 15 , wherein the uncoated digestive enzyme-containing beads have a total protease activity ranging from about 47,000 USP protease units to about 62,000 USP protease units.

18 . The dosage form of claim 5 , in the form of a capsule filled with the multi-particulate digestive enzyme composition.

19 . A method of treating pancreatitis pain, comprising administering the composition of claim 1 to a patient in need thereof.

20 . A method of treating pancreatitis pain and pancreatic insufficiency, comprising administering the composition of claim 1 to a patient in need thereof.

21 . The method of claim 20 , wherein said administering comprises administering, per meal, an amount of multi-particulate digestive enzyme composition such that the lipase activity of the enterically coated digestive enzyme-containing beads ranges from about 8000 to about 40,000 USP lipase units, and the lipase activity of the uncoated digestive enzyme-containing beads ranges from about 40,000 to about 72,000 USP lipase units.

22 . A method of treating pancreatic exocrine insufficiency, comprising administering to a patient in need thereof a therapeutically effective dose of an enterically coated digestive enzyme, wherein said dose ranges from about 100 to about 300 USP lipase units/kg/meal.

23 . The method of claim 22 , wherein the daily dose of said enterically coated digestive enzyme ranges from about 35,000 to about 90,000 USP lipase units.

24 . The method of claim 22 , wherein said the enterically coated digestive enzyme is in the form of a capsule comprising enterically coated digestive enzyme-containing beads;

wherein the enterically coated digestive enzyme-containing beads comprise a core and an enteric coating disposed over the core, wherein the core comprises a therapeutically effective amount of one or more digestive enzymes, and the enteric coating comprises an enteric polymer.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2020
From: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
To: ALLERGAN THERAPEUTICS LLC
Reel/Frame 052538/0196 →
CHANGE OF NAME Recorded Mar 18, 2016
From: APTALIS PHARMA LIMITED
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 038177/0967 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2015
From: VENKATESH, GOPI
To: EURAND PHARMACEUTICALS LIMITED
Reel/Frame 036093/0121 →
CHANGE OF NAME Recorded Jul 15, 2015
From: EURAND PHARMACEUTICALS LIMITED
To: APTALIS PHARMA LIMITED
Reel/Frame 036093/0499 →